Ansar Ali Khan

He worked in various drug discovery organization and held responsible positions for the overall preclinical DMPK-Bioanalytical strategy of several drug discovery and development projects in diverse therapeutic areas such as Metabolic disorders, Anti-inflammatory, Oncology, Anti-infective and CNS. Dr. Ansar along with his team characterized preclinical development of the anti-infective molecule Enmetazobactam at Orchid Research Laboratories Ltd., which has been approved by the European Medicines Agency and USFDA for marketing authorization for the treatment of complicated urinary tract infections.

Dr. Ansar did his master’s in medical Biochemistry from JIPMER, Pondicherry holds a Ph.D. in Drug metabolism from University of Groningen, The Netherlands. He has established a standalone GLP compliant Lab for BCS-based Biowaiver studies with successful FDA approval of a product for marketing authorization. He is also instrumental in establishing an In vitro ADME site with full automation and onboarded several integrated drug discovery programmes for small molecules in various therapeutic areas.

In the past, Dr. Ansar was associated with renowned drug discovery companies (Orchid Research Laboratories Ltd., Glenmark Research Centre, and Dr. Reddy’s Laboratories Ltd.) and Contract research organizations such as Syngene International Ltd., GVK Bioscience Pvt. Ltd., and Vimta Life Sciences Ltd.

Dr. Ansar brings in a unique blend of drug discovery experience in scientifically driving client projects.